Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels-Reference-Cited by-同舟云学术

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels

Published:2022-05 Issue:5 Volume:76 Page:1042-1050
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Sonneveld Milan J.^ORCID,Chiu Shao-Ming,Park Jun Yong,Brakenhoff Sylvia M.,Kaewdech Apichat,Seto Wai-Kay,Tanaka Yasuhito,Carey Ivana,Papatheodoridi Margarita,van Bömmel Florian,Berg Thomas,Zoulim Fabien,Ahn Sang Hoon,Dalekos George N.,Erler Nicole S.,Höner zu Siederdissen Christoph,Wedemeyer Heiner,Cornberg Markus,Yuen Man-Fung,Agarwal Kosh,Boonstra Andre,Buti Maria,Piratvisuth Teerha,Papatheodoridis George,Chen Chien-Hung,Maasoumy Benjamin

Funder

Fujirebio Europe NV

Publisher

Elsevier BV

Subject

Hepatology

Reference20 articles.

1. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study;Marcellin;Lancet,2013

2. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study);Brouwer;Hepatology,2015

3. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study;Berg;J Hepatol,2017

4. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B;Chang;Aliment Pharmacol Ther,2015

5. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study);Liem;Gut,2019

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronische Hepatitis-B- und Hepatitis-D-Virusinfektion;DMW - Deutsche Medizinische Wochenschrift;2024-08

2. Higher hepatitis B core-specific T cell response is associated with a lower risk of clinical relapse after discontinuation of oral antiviral treatment;Journal of Microbiology, Immunology and Infection;2024-08

3. High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy;Liver International;2024-07-15

4. Clinical trial: An open‐label, randomised trial of different re‐start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B;Alimentary Pharmacology & Therapeutics;2024-07-05

5. PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial;Journal of Hepatology;2024-07